Thrivent Financial for Lutherans Reduces Holdings in Repligen Corporation $RGEN

Thrivent Financial for Lutherans lessened its position in shares of Repligen Corporation (NASDAQ:RGEN) by 10.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 411,706 shares of the biotechnology company’s stock after selling 47,114 shares during the period. Thrivent Financial for Lutherans’ holdings in Repligen were worth $67,463,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in RGEN. United Capital Financial Advisors LLC purchased a new stake in Repligen during the 3rd quarter worth about $368,387,000. Holocene Advisors LP lifted its holdings in Repligen by 47.0% during the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after purchasing an additional 440,290 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Repligen during the 4th quarter worth about $199,176,000. Alliancebernstein L.P. lifted its holdings in Repligen by 21.8% during the 3rd quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock worth $147,595,000 after purchasing an additional 197,778 shares in the last quarter. Finally, Conestoga Capital Advisors LLC lifted its holdings in Repligen by 10.6% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after purchasing an additional 101,062 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 0.5%

RGEN opened at $102.87 on Friday. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The stock has a market cap of $5.80 billion, a PE ratio of 114.30, a PEG ratio of 1.99 and a beta of 1.09. The business has a 50 day moving average of $118.96 and a 200-day moving average of $142.18.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts predict that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on RGEN shares. JPMorgan Chase & Co. dropped their price objective on Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. HC Wainwright increased their price objective on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. UBS Group dropped their target price on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Finally, Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $166.15.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.